最新进展与未来展望:眼内注射药物治疗玻璃体视网膜疾病的现状与挑战。
Recent advances and future prospects: Current status and challenges of the intraocular injection of drugs for vitreoretinal diseases.
机构信息
Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University Graduate School of Medicine, Osaka, Japan.
出版信息
Adv Drug Deliv Rev. 2023 Jul;198:114870. doi: 10.1016/j.addr.2023.114870. Epub 2023 May 10.
Effective drug therapy for vitreoretinal disease is a major challenge in the field of ophthalmology; various protective systems, including anatomical and physiological barriers, complicate drug delivery to precise targets. However, as the eye is a closed cavity, it is an ideal target for local administration. Various types of drug delivery systems have been investigated that take advantage of this aspect of the eye, enhancing ocular permeability and optimizing local drug concentrations. Many drugs, mainly anti-VEGF drugs, have been evaluated in clinical trials and have provided clinical benefit to many patients. In the near future, innovative drug delivery systems will be developed to avoid frequent intravitreal administration of drugs and maintain effective drug concentrations for a long period of time. Here, we review the published literature on various drugs and administration routes and current clinical applications. Recent advances in drug delivery systems are discussed along with future prospects.
治疗玻璃体视网膜疾病的有效药物疗法是眼科领域的一大挑战;各种保护系统,包括解剖和生理屏障,使药物难以精确递送到靶部位。然而,由于眼睛是一个封闭的腔,它是局部给药的理想目标。已经研究了各种类型的药物输送系统,利用眼睛的这一方面,提高眼通透性并优化局部药物浓度。许多药物,主要是抗血管内皮生长因子药物,已经在临床试验中进行了评估,并为许多患者提供了临床益处。在不久的将来,将开发创新的药物输送系统,以避免频繁玻璃体内给予药物,并长时间维持有效的药物浓度。在这里,我们回顾了关于各种药物和给药途径以及当前临床应用的已发表文献。讨论了药物输送系统的最新进展及其未来前景。